ArticleCurrent microbiology2025
Advanced Peptide Nanozymes with Dual Antifungal Mechanisms: Cutting-Edge Innovations in Combatting Antimicrobial Resistance.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This letter commends the recent innovative research findings on "Dual-Action Antifungal Peptide Nanozymes: A Novel Approach to Combatting Antimicrobial Resistance." The study introduces a pioneering method to address antimicrobial resistance by developing peptide nanozymes that mimic antimicrobial peptides and enzymes through de novo design and peptide assembly. The heptapeptide IHIHICI, designed using AlphaFold2 and molecular dynamics simulations, exhibits high stability and dual antifungal actions, effectively killing over 90% of Candida albicans within 10 min. This research represents a significant advancement in the development of multifunctional antimicrobial materials, with promising biomedical applications.
Indexed as
Identifiers
39885083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.